Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
- Interventions
- Registration Number
- NCT00447057
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival \[PFS\], disease control rate, best response rate, time to treatment failure \[TTTF\], overall survival \[OS\] and 1-year survival rates) compared to pemetrexed plus erlotinib combination.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 204
- Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy.
- Failure of previous treatment with one prior platinum-based chemotherapy regimen.
- Good performance status.
- Adequate bone marrow reserve, renal and hepatic functions.
- Serious concomitant systemic disease.
- Inability to take oral medication.
- Inability or unwillingness to take vitamin supplementation and corticosteroids.
- Pregnancy / Breast-feeding.
- Treatment with certain medicines that prevent blood from clotting.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pemetrexed (Nonsquamous) Pemetrexed Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm Pemetrexed + Erlotinib (Nonsquamous) Pemetrexed Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm Pemetrexed (Squamous) Pemetrexed Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm Pemetrexed + Erlotinib (Squamous) Pemetrexed Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm Pemetrexed + Erlotinib (Nonsquamous) Erlotinib Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm Pemetrexed + Erlotinib (Squamous) Erlotinib Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) Baseline to date of measured PD or death from any cause. Maximum follow-up was from baseline to 32.2 months PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria using computed tomography (CT) or magnetic resonance imaging (MRI) for objective determination of progressive disease (PD: ≤20% increase in sum of longest diameter of target lesion). For participants alive as of data cut-off date who did not have PD, PFS was censored at date of last CT/MRI. For participants who received subsequent systemic anticancer therapy (after study discontinuation) prior to PD or death, PFS censored at date of last CT/MRI prior to initiation of post discontinuation systemic anticancer therapy.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate) Baseline to measured PD. Maximum follow-up was from Baseline to 34 months Per RECIST:
CR: Disappearance of all target lesions; PR: Either a) ≤30% decrease in sum of longest diameter (LD) of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) of ≥1 nontarget lesions. In either case, no new lesions may have appeared.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.
PD: ≤20% increase in sum of LD of target lesions. Disease Control Rate (%) = (SD+PR+CR)/number of participants in arm\*100.Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate) Baseline to measured progressive disease. Maximum follow-up was from Baseline to 34 months CR: Disappearance of all tumor lesions; PR: Either a) at least a 30% decrease in sum of LD of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) ≥1 nontarget lesions. In either case, no new lesions may have appeared.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.
PD: ≤20% increase in the sum of LD of target lesions. Response Rate (%) = (CR+PR)/number of participants in arm\*100.Time to Treatment Failure (TTTF) Baseline to first date among death from any cause, PD, or study treatment discontinuation for any reason other than "protocol complete" or "satisfactory response". Maximum follow-up was from Baseline to 32.2 months Defined as the time from randomization to death from any cause, first observation of PD, or study treatment discontinuation due to any reason other than "protocol complete" or "satisfactory response". For participants who discontinued due to "protocol complete" or "satisfactory response", or for participants not known to have discontinued as of the data cut-off date, TTTF was censored at the last contact date.
Overall Survival (OS) Baseline to date of death from any cause. Maximum follow-up was from Baseline to 42.6 months. OS time is the duration from randomization to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date, OS was censored at the date of last contact.
Percentage of Participants Surviving at 1 Year Baseline to date of death from any cause up to 1 year Overall Survival (OS) rate at 1 year from the date of randomization was determined using the distribution of OS times and was estimated using the Kaplan-Meier method.
Number of Participants With Adverse Events (AEs) Baseline up to 42.2 months Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇸🇪Solna, Sweden